drugset / Trial / NCT00146289

The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects

NCT00146289

Phase 2 Completed 138 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to determine whether MICARDIS® improves insulin sensitivity in overweight or obese, non-diabetic, normotensive subjects.

Timeline

Start
2005-02
Primary completion
2005-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Telmisartan Other / unclassified 160 mg

Indications